WO2004038407A3 - Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12) - Google Patents

Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12) Download PDF

Info

Publication number
WO2004038407A3
WO2004038407A3 PCT/EP2003/011391 EP0311391W WO2004038407A3 WO 2004038407 A3 WO2004038407 A3 WO 2004038407A3 EP 0311391 W EP0311391 W EP 0311391W WO 2004038407 A3 WO2004038407 A3 WO 2004038407A3
Authority
WO
WIPO (PCT)
Prior art keywords
diseases
gpr12
human
therapeutics
diagnostics
Prior art date
Application number
PCT/EP2003/011391
Other languages
French (fr)
Other versions
WO2004038407A2 (en
Inventor
Stefan Golz
Ulf Brueggemeier
Holger Summer
Original Assignee
Bayer Healthcare Ag
Stefan Golz
Ulf Brueggemeier
Holger Summer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag, Stefan Golz, Ulf Brueggemeier, Holger Summer filed Critical Bayer Healthcare Ag
Priority to AU2003276106A priority Critical patent/AU2003276106A1/en
Publication of WO2004038407A2 publication Critical patent/WO2004038407A2/en
Publication of WO2004038407A3 publication Critical patent/WO2004038407A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
    • G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH

Abstract

The invention provides a human GPR12 which is associated with the hematological diseases, cardiovascular diseases, dermatological diseases, disorders of the peripheral and central nervous system, urological diseases, reproduction disorders and cancer. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, dermatological diseases, disorders of the peripheral and central nervous system, urological diseases, reproduction disorders and cancer. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR12 as well as pharmaceutical compositions comprising such compounds.
PCT/EP2003/011391 2002-10-24 2003-10-15 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12) WO2004038407A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003276106A AU2003276106A1 (en) 2002-10-24 2003-10-15 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02023768 2002-10-24
EP02023768.1 2002-10-24

Publications (2)

Publication Number Publication Date
WO2004038407A2 WO2004038407A2 (en) 2004-05-06
WO2004038407A3 true WO2004038407A3 (en) 2004-11-11

Family

ID=32116224

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2003/011391 WO2004038407A2 (en) 2002-10-24 2003-10-15 Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)

Country Status (2)

Country Link
AU (1) AU2003276106A1 (en)
WO (1) WO2004038407A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2605574A1 (en) * 2004-04-20 2005-11-03 Galapagos N.V. Methods, compositions and compound assays for inhibiting amyloid-beta protein production
JP2010527375A (en) * 2007-05-15 2010-08-12 ヘリコン セラピューティクス，インコーポレイテッド Method for treating cognitive impairment by inhibition of GPR12

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021987A2 (en) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
WO2001048483A2 (en) * 1999-12-10 2001-07-05 Astrazeneca Ab Method for screening of appetite control agents
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000021987A2 (en) * 1998-10-13 2000-04-20 Arena Pharmaceuticals, Inc. A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
WO2001048483A2 (en) * 1999-12-10 2001-07-05 Astrazeneca Ab Method for screening of appetite control agents
WO2002061087A2 (en) * 2000-12-19 2002-08-08 Lifespan Biosciences, Inc. Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL EBI; 20 April 2000 (2000-04-20), XP002282437, retrieved from EBI Database accession no. AAY90896 *
DATABASE EMBL EBI; 8 August 2002 (2002-08-08), XP002282183, retrieved from EBI Database accession no. ABP81881 *
PYNE S ET AL: "REVIEW ARTICLE SPHINGOSINE 1-PHOSPHATE SIGNALLING IN MAMMALIAN CELLS", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, GB, vol. 349, 2000, pages 385 - 402, XP000939036, ISSN: 0264-6021 *
UHLENBROCK K ET AL: "Sphingosine 1-phosphate is a ligand of the human gpr3, gpr6 and gpr12 family of constitutively active G protein-coupled receptors", CELLULAR SIGNALLING, ELSEVIER SCIENCE LTD, GB, vol. 14, no. 11, 12 June 2002 (2002-06-12), ONLINE, pages 941 - 953, XP002229984, ISSN: 0898-6568 *

Also Published As

Publication number Publication date
AU2003276106A1 (en) 2004-05-13
AU2003276106A8 (en) 2004-05-13
WO2004038407A2 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
WO2005093092A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44)
WO2003074069A3 (en) Diagnostics and therapeutics for diseases associated with the n-formyl peptide receptor 1 (fpr 1)
WO2004042389A3 (en) Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4d (pde4d)
WO2005040828A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 49 (gpr49)
WO2004080373A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
WO2004042402A3 (en) Diagnostics and therapeutics for diseases associated with human mas-related gene x1 (mrgx1)
WO2004038405A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 43 (gpr43)
WO2004038407A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12)
WO2004071378A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor hm74a (hm74a)
WO2003095967A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 9(ccr9)
WO2004038421A3 (en) Diagnostics and therapeutics for diseases associated with human g protein-coupled receptor 41 (gpr41)
WO2004104574A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 7 (ccr7)
WO2005031345A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor adipor2 (adipor2)
WO2004042405A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 3 (gpr3)
WO2004038416A8 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 6 (gpr6)
WO2003096020A3 (en) Diagnostics and therapeutics for diseases associated with chemokine receptor 8 (ccr8)
WO2004015427A3 (en) Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 19 (gpr19)
WO2004038408A3 (en) Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 14 (gpr14)
WO2004015422A3 (en) Diagnostics and therapeutics for diseases associated with ovarian cancer g-protein coupled receptor 1 (ogr-1)
WO2005095953A3 (en) Diagnostics and therapeutics for diseases associated with c-c chemokine receptor type 6 (ccr6)
WO2005040825A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 20 (gpr20)
WO2004048978A3 (en) Diagnostics and therapeutics for diseases associated with bile acid g-protein-coupled receptor 37 (bg37)
WO2005040790A3 (en) Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 75 (gpr75)
WO2003066077A3 (en) Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1)
WO2004099248A3 (en) Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP